DiscoverIn the Thick of ItNavigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients
Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients

Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients

Update: 2024-03-13
Share

Description

When should we make the critical decision to start Cardiac Myosin therapy in NYHA Class II HCM patients? Today, Dr. Patrycja Galazka is joined by Dr. Sara Saberi, Assistant Associate Professor in Cardiovascular Medicine and co-director of the Inherited Cardiomyopathy Program at the Frankel Cardiovascular Center. Together, we dive into the intricate world of Cardiac Myosin Inhibitors, addressing this vital question.

In the ever-changing landscape of HCM management, this episode offers a beacon of clarity. Whether you're a healthcare professional dedicated to improving patient outcomes or someone personally navigating the challenges of HCM, our conversation provides essential insights. Join us for a discussion that could reshape your approach to HCM care.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients

Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients

Hypertrophic Cardiomyopathy Medical Society